Increased BMI is associated with significantly larger MI risk reduction with GLP-1RA, implying that weight reduction may further reduce residual ASCVD risk with GLP-1RA use
10.1038/s41580-024-00703-5 36 DixonS
Subgroup analyses were not reweighted between the subgroup of semaglutide and DPP4i users, and only bivariate analyses were conducted in subgroup analyses
This is because it is approved for weight loss and the higher doses may not be suitable for type 2 diabetes
In addition, RNA-levels do not always represent the functional expression of the ion channels, as these proteins are subject to post-translational modifications
The safer comparison asks what is approved, what evidence is mature, what risks apply, and what monitoring a clinician can provide